Lumavita: Innovation in Anti-Infectives

Lumavita is an independent, specialty biopharmaceutical company focused on global development and commercialisation of novel anti-infectives for women’s health.

Lumavita is based in Basel, Switzerland, home to a significant and growing biopharmaceutical sector.


Lumavita’s first product, FemiFect® (pentamycin), a broad-spectrum macrolide antibiotic, is approved in Switzerland for the treatment of vaginitis.  Additional regulatory submissions are pending in many countries around the world and Lumavita’s pipeline includes a Phase IIb dose-optimisation programme for pentamycin.  In Phase I clinical trials at Lumavita is SPK-601, the first in a new class of drugs known as PC-PLC inhibitors¹.  SPK-601 has the potential to combat viral infections such as those caused by human papiloma virus (HPV) and herpes simplex virus (HSV).

FemiFect (pentamycin) is the first broad-spectrum
tree cutting Homestead tree removal Homestead FL Minnetonka tree removal tree service Grand Forks ND tree pruning Grand Forks ND tree service in Freeport NY tree pruning in Freeport NY Boulder CO tree pruning Alameda tree removal tree removal Alameda CA tree cutting Bell Vancouver tree services Charleston tree services tree pruning Redding CA tree removal Redding CA tree services Pharr tree services in Alexandria tree removal Alexandria LA Fort Myers tree trimming tree trimming Wauwatosa Wauwatosa WI tree pruning tree services Charlottesville tree service Charlottesville VA tree cutting Jacksonville Jacksonville tree services Bradenton FL tree cutting tree service in Bradenton FL tree pruning Ventura CA tree services Ventura Peoria tree services tree cutting Peoria Davenport IA tree service Davenport tree services
antibiotic approved to treat all three of the most common infections known to cause vaginitis: bacteria, fungi and protozoa. Vaginitis is a common disorder affecting up to 10% of women around the world every year.  Current empirical treatments for vaginitis do not cover all three types of infections and, as a result, many patients fail to respond adequately to treatment and recurrence rates are high.  Because FemiFect has a uniquely broad spectrum of activity it is a natural first choice for empirical use in treating vaginitis.


Lumavita has established a network of partnerships with distributors in Switzerland and around the world in preparation for the imminent launch of FemiFect.


Lumavita AG is led by a highly experienced management team with a strong track record in commercialisation, development and regulatory in both the pharmaceutical and biotechnology industries.  The company’s approach is an asset-light business model with outsourcing of laboratory, clinical trial and manufacturing requirements.

¹ phosphatidylcholine-specific phospholipase C

© 2008 Copyright Lumavita AG All rights reserved.